Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

LIGAND PHARMACEUTICALS INC: Janus Henderson Group Ltd. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Janus Henderson Group Ltd. amended its Schedule 13G stake filing for Ligand Pharmaceuticals Inc., disclosing the change to the SEC under accession number 0001274173-26-000265. The filing updates the asset manager's previously reported beneficial ownership position in the biopharmaceutical company. Schedule 13G amendments are typically filed by institutional investors whose holdings shift, though the filing summary did not specify the revised share count or percentage. The disclosure matters because it signals a change in a major institutional holder's exposure to Ligand, a company whose revenue depends on royalty streams and milestone payments from partnered drug programs. Investors will watch for the full filing details to see whether Janus Henderson increased or trimmed its position, and for any subsequent 13F or 13G updates that clarify the size and direction of the stake.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Ligand Pharmaceuticals Inc, Janus Henderson Group Ltd.